Precision For Medicine
2 Bethesda Metro Center
Precision for Medicine (Precision) was founded in 2012 by life science entrepreneurs Ethan Leder and Mark Clein. Financed by $150 million in equity capital, Precision focuses on the service needs associated with discovering, developing, and marketing next generation drugs, diagnostics, and medical devices. Leder and Clein, together with their core management team and investors, have a track record of creating, building, and managing highly successful, science-based service organizations that address emerging product development and commercialization challenges in the life sciences industry.
Since its inception, Precision has invested heavily in all facets of its business, and today, Precision’s team includes more than 250 employees across 6 campuses. The Precision for Medicine Advisors help drive innovative solutions for our customers by providing leading edge thought leadership to organizations and customer groups looking to navigate tomorrow’s healthcare trends. Our scientists and industry experts offer decades of experience in the research and clinical development of targeted therapies and diagnostics, biorepository, specimen management and clinical solutions, regulatory guidance, commercialization planning, and market adoption.
In 1999, Leder and Clein founded U.S. Bioservices, a leading provider of distribution and support services for specialty pharmaceuticals. AmeriSourceBergen acquired U.S. Bioservices in 2003. Later that year, Leder and Clein formed United BioSource Corporation (UBC), a provider of post-approval scientific and medical affairs services that became a leading research and commercialization partner to biopharmaceutical companies focused exclusively on addressing the issues of cost effectiveness and safety in the post-approval market. In 2010, Medco Health Solutions, Inc. (now part of Express Scripts Inc.) acquired UBC.
Based on their experiences with U.S. Bioservices and UBC, as well as more than 20 years of building leading edge healthcare companies, Leder and Clein turned their attention to the emerging service needs associated with next generation drugs, diagnostics, and medical devices.
Precision For Medicine